Recruitment of quiescent tumor by humoral stimulatory activity: Requirements for successful chemotherapy

P. J. Burke, Judith Karp, W. P. Vaughan, P. L. Sanford

Research output: Contribution to journalArticle

Abstract

Acute leukemia is a heterogeneous tumor with respect to cellular proliferation and is sensitive to positive and negative growth control factors. Tumor associated inhibitory activity (TAIA) and simultaneously present humoral stimulatory activity (HSA) in this disease may be modulated by timed sequential chemotherapy to increase tumor growth at a predictable time and make it more sensitive to accurately administered drug. Our in vivo studies of timed sequential chemotherapy in human leukemia demonstrate that an increase in tumor labeling index (LI) temporally coincides with the detection of HSA following drug administration. Maximal HSA occurs at a predictable time following initial administration of the aplasia-producing drug and is coincident with an increased LI of recovering normal marrow granulocytic elements and marrow tumor cells. These studies demonstrate the salutary effect of drugs given in high dose to reduce tumor mass and recruit tumor cells to further high-dose drug sensitivity.

Original languageEnglish (US)
Pages (from-to)519-533
Number of pages15
JournalBlood Cells
Volume8
Issue number3
StatePublished - 1982

Fingerprint

Drug Therapy
Neoplasms
Pharmaceutical Preparations
Leukemia
Bone Marrow
Intercellular Signaling Peptides and Proteins
Cell Proliferation
Growth

ASJC Scopus subject areas

  • Hematology

Cite this

Recruitment of quiescent tumor by humoral stimulatory activity : Requirements for successful chemotherapy. / Burke, P. J.; Karp, Judith; Vaughan, W. P.; Sanford, P. L.

In: Blood Cells, Vol. 8, No. 3, 1982, p. 519-533.

Research output: Contribution to journalArticle

Burke, P. J. ; Karp, Judith ; Vaughan, W. P. ; Sanford, P. L. / Recruitment of quiescent tumor by humoral stimulatory activity : Requirements for successful chemotherapy. In: Blood Cells. 1982 ; Vol. 8, No. 3. pp. 519-533.
@article{0f6c1f7294974f37b3a3b91afaf49f20,
title = "Recruitment of quiescent tumor by humoral stimulatory activity: Requirements for successful chemotherapy",
abstract = "Acute leukemia is a heterogeneous tumor with respect to cellular proliferation and is sensitive to positive and negative growth control factors. Tumor associated inhibitory activity (TAIA) and simultaneously present humoral stimulatory activity (HSA) in this disease may be modulated by timed sequential chemotherapy to increase tumor growth at a predictable time and make it more sensitive to accurately administered drug. Our in vivo studies of timed sequential chemotherapy in human leukemia demonstrate that an increase in tumor labeling index (LI) temporally coincides with the detection of HSA following drug administration. Maximal HSA occurs at a predictable time following initial administration of the aplasia-producing drug and is coincident with an increased LI of recovering normal marrow granulocytic elements and marrow tumor cells. These studies demonstrate the salutary effect of drugs given in high dose to reduce tumor mass and recruit tumor cells to further high-dose drug sensitivity.",
author = "Burke, {P. J.} and Judith Karp and Vaughan, {W. P.} and Sanford, {P. L.}",
year = "1982",
language = "English (US)",
volume = "8",
pages = "519--533",
journal = "Blood Cells, Molecules, and Diseases",
issn = "1079-9796",
publisher = "Academic Press Inc.",
number = "3",

}

TY - JOUR

T1 - Recruitment of quiescent tumor by humoral stimulatory activity

T2 - Requirements for successful chemotherapy

AU - Burke, P. J.

AU - Karp, Judith

AU - Vaughan, W. P.

AU - Sanford, P. L.

PY - 1982

Y1 - 1982

N2 - Acute leukemia is a heterogeneous tumor with respect to cellular proliferation and is sensitive to positive and negative growth control factors. Tumor associated inhibitory activity (TAIA) and simultaneously present humoral stimulatory activity (HSA) in this disease may be modulated by timed sequential chemotherapy to increase tumor growth at a predictable time and make it more sensitive to accurately administered drug. Our in vivo studies of timed sequential chemotherapy in human leukemia demonstrate that an increase in tumor labeling index (LI) temporally coincides with the detection of HSA following drug administration. Maximal HSA occurs at a predictable time following initial administration of the aplasia-producing drug and is coincident with an increased LI of recovering normal marrow granulocytic elements and marrow tumor cells. These studies demonstrate the salutary effect of drugs given in high dose to reduce tumor mass and recruit tumor cells to further high-dose drug sensitivity.

AB - Acute leukemia is a heterogeneous tumor with respect to cellular proliferation and is sensitive to positive and negative growth control factors. Tumor associated inhibitory activity (TAIA) and simultaneously present humoral stimulatory activity (HSA) in this disease may be modulated by timed sequential chemotherapy to increase tumor growth at a predictable time and make it more sensitive to accurately administered drug. Our in vivo studies of timed sequential chemotherapy in human leukemia demonstrate that an increase in tumor labeling index (LI) temporally coincides with the detection of HSA following drug administration. Maximal HSA occurs at a predictable time following initial administration of the aplasia-producing drug and is coincident with an increased LI of recovering normal marrow granulocytic elements and marrow tumor cells. These studies demonstrate the salutary effect of drugs given in high dose to reduce tumor mass and recruit tumor cells to further high-dose drug sensitivity.

UR - http://www.scopus.com/inward/record.url?scp=0020364168&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0020364168&partnerID=8YFLogxK

M3 - Article

C2 - 7159763

AN - SCOPUS:0020364168

VL - 8

SP - 519

EP - 533

JO - Blood Cells, Molecules, and Diseases

JF - Blood Cells, Molecules, and Diseases

SN - 1079-9796

IS - 3

ER -